Ivan Kairatov is a leading biopharma expert with a profound background in molecular oncology and therapeutic innovation. His extensive research in drug development has centered on the complex interplay between tumor biology and the microenvironment, particularly how cellular communication drives cancer progression. In this discussion, we explore the recent breakthroughs regarding the Jagged1 protein and its role in remodeling the extracellular matrix to facilitate metastasis in aggressive breast cancers. We delve into the “vicious cycle” of TGFβ signaling, the physical changes in tissue structure that allow cancer cells to migrate, and the potential for new targeted therapies to improve outcomes for patients with hormone-receptor-negative subtypes.
Jagged1 is often highly expressed in aggressive, hormone-receptor-negative breast cancers. How does this protein facilitate communication between cancer cells and fibroblasts, and what specific changes does this trigger in the surrounding tissue structure?
Jagged1 acts as a critical molecular bridge, sitting on the surface of breast cancer cells and reaching out to interact directly with neighboring fibroblasts. When this contact occurs, it sends a powerful signal to those fibroblasts, effectively hijacking their normal role in tissue maintenance and forcing them to overproduce extracellular matrix components like collagen. This isn’t just a matter of quantity; the Jagged1-activated fibroblasts actively remodel the architecture of the tissue, transforming a chaotic mesh into a highway of highly aligned, linearized matrix fibers. These straight paths are devastating for the patient, as they serve as physical tracks that cancer cells use to migrate away from the primary tumor and toward the bloodstream.
The relationship between TGFβ signaling and matrix stiffness appears to create a self-reinforcing loop in tumor environments. Could you explain the step-by-step progression of this cycle and how it influences the physical alignment of collagen fibers to aid metastasis?
This cycle is a classic example of a “vicious loop” where the tumor’s biology and its physical environment feed off each other to accelerate the disease. It begins when high levels of Jagged1 trigger the activation of the transforming growth factor beta (TGFβ) pathway, a master regulator that forces the tissue into a state of fibrosis. As TGFβ drives massive collagen deposition, the tumor environment becomes increasingly stiff and rigid, which in turn signals the cancer cells to express even more Jagged1 on their surfaces. This increased stiffness acts as a mechanical cue that reinforces the linearization of fibers, creating a streamlined environment where the cancer cells can move with high efficiency. Breaking this 18.3.2026 published finding down, we see that the mechanical “crunch” of the tumor is not just a symptom, but a driver that sustains the aggressive signaling pathways.
Aggressive breast cancers currently lack many targeted therapy options, leading to poorer prognoses. How might disrupting the Jagged1-mediated remodeling process change the treatment landscape, and what practical challenges exist when trying to intervene in these signaling pathways?
Disrupting the Jagged1-mediated remodeling process could be a game-changer for triple-negative and other hormone-receptor-negative breast cancers that currently have limited options beyond systemic chemotherapy. By targeting this communication channel, we could potentially stop the “retooling” of the surrounding tissue, effectively taking away the paths the cancer needs to spread to distant organs. However, the practical challenge lies in the fact that these pathways, like TGFβ and Jagged1, often have roles in healthy tissue repair, so we must find a way to inhibit them specifically within the tumor microenvironment. Furthermore, because this is a self-reinforcing loop, a successful therapy might need to address both the chemical signaling and the physical stiffness of the matrix simultaneously to prevent the cycle from restarting.
Metastasis significantly reduces survival rates compared to localized breast cancer. In what ways does the remodeling of the extracellular matrix directly facilitate the spread of cells to distant organs, and what methods are used to measure this aggressive transition?
The remodeling of the extracellular matrix turns a protective barrier into a launchpad for cancer cells, which explains why survival rates drop so dramatically once the disease moves beyond its local origin. When the matrix becomes linearized and stiff, it essentially provides a low-resistance path that allows cancer cells to “crawl” toward blood vessels with much greater speed and directionality than they could in healthy tissue. Researchers measure this aggressive transition by utilizing advanced cancer model systems and analyzing patient data to correlate Jagged1 expression with actual survival outcomes and the physical density of collagen. By tracking these structural changes alongside biological milestones like TGFβ activity levels, we can visualize how the tumor prepares its own escape route long before the cells actually appear in distant organs.
What is your forecast for breast cancer treatment?
I forecast that the next decade of breast cancer treatment will shift from focusing solely on the “seeds”—the cancer cells themselves—to targeting the “soil,” which is the remodeled extracellular matrix. We will likely see the emergence of dual-action therapies that combine traditional tumor-killing agents with inhibitors that break the Jagged1-TGFβ feedback loop to “soften” the tumor and prevent metastasis. By integrating mechanical biology with molecular pharmacology, we will finally be able to offer personalized protocols for patients with aggressive subtypes, potentially turning a once-lethal metastatic diagnosis into a manageable localized condition. This research published in March 2026 marks the beginning of a move toward therapeutic strategies that treat the tumor as an integrated ecosystem rather than an isolated group of cells.
